Pharma faces an existential crisis. The cost and time lines of developing new medications have been growing exponentially for decades, with no end in sight. Could modeling and simulation approaches be the Next Great Hope for ending this madness and restoring sustainability to drug development? At the same time, can it deliver on the promise of […]Read More
Author: Kevin Feng
Dr. Kevin Feng is the director of the scientific group in the software business unit at Certara. His interests include using PBPK models, PK/PD models, and clinical trial simulation/design to aid decision-making, pharmacoeconomics, and personalized medicine. He earned his doctorate in systems control engineering at the University of Sheffield.